Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. 4 hr ago

    Managing Glaucoma in Pregnancy 2026: Evidence and Consensus

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/managing-glaucoma-in-pregnancy-2026-evidence-and-consensus Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Managing Glaucoma in Pregnancy 2026: Evidence and Consensus Evidence cutoff: July 24, 2026 Pregnancy does not automatically make glaucoma treatment unsafe, and stopping glaucoma medication without medical supervision can permanently threaten vision. The goal is to protect the pregnant patient’s optic nerve while reducing avoidable exposure of the fetus or breastfed infant to glaucoma medicines. The best available evidence remains limited. There are no large randomized trials of glaucoma treatment during pregnancy. Current recommendations rely on medication labels, animal reproductive studies, pharmacokinetic research, retrospective case series, case reports, and expert consensus. The most current major guidance includes the 2026 American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern, the American Glaucoma Society and Canadian Glaucoma Society practical guide, and updated clinical reviews. () > Important: This article is educational and cannot replace individualized care from a glaucoma specialist, obstetric clinician, and—when appropriate—a pediatric or neonatal clinician. Key recommendations at a glance Plan before conception whenever possible. Establish a target pressure, document the optic nerve and visual field, review medications, and consider laser treatment or surgery before pregnancy if glaucoma is advanced or difficult to control. Do not assume that pregnancy will lower pressure enough. Intraocular pressure often falls, but some patients with established glaucoma experience pressure elevation or visual field progression. Use the fewest medicines at the lowest effective exposure. Punctal occlusion and gentle eyelid closure should be used after every drop. Brimonidine is commonly preferred when a glaucoma drop is needed during pregnancy, but it should be stopped before delivery and avoided during breastfeeding because of possible infant central nervous system depression and apnea. Timolol may be used selectively, particularly when the maternal benefit is important, but fetal growth and heart rate should be considered, and newborns may require observation after late-pregnancy exposure. Topical carbonic anhydrase inhibitors such as dorzolamide or brinzolamide are possible alternatives when needed, although human pregnancy and milk data are limited. Oral acetazolamide is generally reserved for serious or refractory pressure elevation. It is often considered acceptable during breastfeeding, but exposure near delivery has occasionally been associated with temporary neonatal metabolic acidosis. Prostaglandin analogues are not first-line during pregnancy because of a theoretical risk of uterine contraction or premature labor and limited human data. Selective laser trabeculoplasty may reduce or eliminate medication exposure. Guidance differs slightly on first-trimester elective treatment, so timing should depend on disease severity and urgency. Incisional surgery is unusual but justified when vision is at meaningful risk. If it cannot be deferred, the second trimester is generally preferred, with local anesthesia and avoidance of antimetabolites whenever possible. How pregnancy changes intraocular pressure Normal physiologic changes Intraocular pressure usually decreases during pregnancy. Proposed explanations include: Increased aqueous humor outflow related to hormonal changes Reduced episcleral venous pressure Effects of progesterone and relaxin Pregnancy-related changes in blood chemistry and vascular physiology One study found that average intraocular pressure in the first trimester was approximately 2 millimeters of mercury higher than in the third trimester. Another study reported an approximately 19.6% reduction in women without ocular hypertension and a 24.4% reduction in women with ocular hypertension, although these studies were relatively small and older. () Pregnancy can also change corneal thickness and biomechanics, which may influence applanation pressure readings. For this reason, clinicians should interpret pressure trends together with the optic nerve, retinal nerve fiber layer imaging, and visual field—not pressure alone. In one review, both intraocular pressure and central corneal thickness had returned toward first-trimester values by approximately three months after delivery. () Why glaucoma can still worsen The average fall in pressure does not protect every patient. In a retrospective series of 28 eyes from 15 women with glaucoma: 57.1% had stable pressure without visual field progression. 17.9% developed visual field progression even though pressure was stable or increased. 17.9% developed pressure elevation without documented visual field progression. Two eyes had inconclusive data. Many patients required glaucoma medication during pregnancy. () The practical lesson is important: a lower pregnancy pressure does not prove that glaucoma is stable, and a normal-looking pressure does not exclude progression. Monitoring during pregnancy and after delivery Minimum monitoring At a minimum, a pregnant patient with established glaucoma should generally be assessed at least once during each trimester. This is a consensus-based recommendation rather than one supported by a large pregnancy trial. () A useful examination may include: Visual acuity Intraocular pressure using the same method when possible Optic nerve examination and photographs Visual field testing when the patient can perform it reliably Optical coherence tomography of the retinal nerve fiber layer and ganglion cell layer Gonioscopy when angle status is uncertain or angle closure is possible Medication review, adherence, and drop technique Heart rate and respiratory history if a beta-blocker is being used Practical monitoring intervals The following schedule is a practical risk-based framework, not a universally validated guideline: For the full table, please open this article on visualfieldtest.com. A visual field and structural baseline should ideally be obtained before conception. Repeating both tests once per trimester may be reasonable for moderate or advanced disease if the patient can tolerate testing, but excessive testing can create fatigue and unreliable results. Postpartum pressure rebound Pressure may rise again after delivery as pregnancy-related physiologic changes resolve. This may be especially important when medication was reduced or stopped during pregnancy. A postpartum plan should therefore be made before delivery rather than waiting for symptoms, because glaucoma progression is often silent. () Medication safety during pregnancy and breastfeeding A note about “pregnancy categories” Many older articles describe glaucoma medicines as Category B or Category C. The United States Food and Drug Administration replaced the former letter categories with descriptive pregnancy and lactation labeling in 2015. The older categories may still appear in reviews, but they should not be interpreted as modern, precise safety rankings. The current labeling emphasizes the quality of human data, animal findings, and the balance between maternal benefit and fetal or infant risk. () Medication comparison For the full table, please open this article on visualfieldtest.com. Brimonidine Brimonidine is frequently described as the preferred first medication during pregnancy because animal studies did not demonstrate fetal malformations at exposures substantially above typical ophthalmic exposure. However, current United States product labeling states that human pregnancy data are inadequate and that the medicine should be used only when the maternal benefit justifies potential fetal risk. () The more important issue is the newborn. Brimonidine crosses the blood-brain barrier and has been associated with central nervous system depression, excessive sleepiness, hypotension, bradycardia, and apnea in infants exposed directly to the medication. Animal studies also demonstrate transfer into milk. For this reason, the American Glaucoma Society handout and product labeling recommend stopping brimonidine before delivery and avoiding it during breastfeeding. () The precise stopping date is not established by high-quality evidence. A practical plan is to discontinue it well before expected delivery, with the exact timing based on disease severity, the alternative treatment, and obstetric and neonatal advice. There are a few reports of breastfeeding without apparent harm, but these involve very small numbers and sometimes multiple medications. LactMed therefore acknowledges the limited reassuring reports while also noting that manufacturers and many clinicians recommend avoiding brimonidine because the potential consequences in a newborn could be serious. () Timolol and other beta-blockers Topical timolol is systemically absorbed and can cross the placenta. Potential fetal or neonatal concerns include a slow heart rate and low blood pressure. Current clinical guidance supports selective use with the lowest effective exposure and consideration of fetal heart-rate and growth monitoring, especially with prolonged or late-pregnancy treatment. () The American Glaucoma Society has suggested that clinicians may consider reducing exposure—for example, using a lower concentration when clinically adequate—but patients should not change concentr Support the show

    Managing Glaucoma in Pregnancy 2026: Evidence and Consensus
  2. 1 day ago

    Wound Healing Modulation 2026: Anti-fibrotics in Filtering Surgery

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/wound-healing-modulation-2026-anti-fibrotics-in-filtering-surgery Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Wound Healing Modulation 2026: Anti-fibrotics in Filtering Surgery Glaucoma filtering surgeries (like trabeculectomy or tube shunts) lower eye pressure by draining fluid out of the eye into a tiny reservoir or bleb under the conjunctiva. After surgery, the eye’s natural wound-healing response (scarring) can close off this drainage, causing the surgery to fail. To prevent excessive scarring, surgeons use anti-fibrotic medications during or after surgery. The most common agents are Mitomycin C (MMC) and 5-fluorouracil (5-FU). These drugs help keep the drainage channel open, improving long-term success. For example, in one study about 95% of eyes reached targets at 6–12 months after trabeculectomy with either MMC or 5-FU (). In other words, both drugs greatly boost the chances of success. Over the past decades and into 2026, new strategies have appeared alongside MMC and 5-FU. Rho-kinase (ROCK) inhibitors and anti-VEGF injections are emerging as wound-healing modulators. Research (in animals and small trials) suggests these may further reduce scarring in filtration surgery () (). In all cases, surgeons balance the benefits of better pressure control against risks of a very thin or leaking bleb (which can lead to infection). Below we summarize the evidence on dosing, outcomes, and safety of these therapies through mid-2026. Anti-Fibrotic Medications: How and How Much Mitomycin C (MMC) Mitomycin C (MMC) is a potent anti-scarring drug originally used in chemotherapy. In glaucoma surgery, it is applied as eye drops or soaked sponges under the conjunctiva at the time of surgery. Standard practice (for many years) is to use MMC at about 0.2 to 0.4 mg/mL concentration for 1–3 minutes on sponges covering the scleral flap area. (For example, the FDA-approved kit “Mitosol” provides 0.2 mg/mL and directs surgeons to apply saturated sponges for 2 minutes ().) In practice, surgeons tailor the dose: a routine case might get 0.2 mg/mL for 2 minutes, while a high-risk case (see risk section below) might get 0.4–0.5 mg/mL. After soaking, the area is rinsed with fluid to stop the drug’s action. Example dosing: In one clinical trial, surgeons applied MMC 0.2 mg/mL for 2 minutes versus 5-FU 50 mg/mL for 5 minutes during trabeculectomy (). Another study on the new PRESERFLO microshunt used 0.2–0.4 mg/mL MMC, lowering mean eye pressure from 21.7 to 14.1 mmHg at 2 years (). Patients given the higher 0.4 mg/mL dose were more likely to be off all medications at 2 years. MMC is very effective at keeping the bleb draining, giving excellent long-term pressure control in many patients (). In the 5-year study above, average pressure with MMC was 9.9 mmHg (from 25.8 pre-op) (), and success was high. However, MMC carries notable risks because it creates a thin, avascular (poorly blood-supplied) bleb. In that same study, about 15% of eyes developed late bleb leaks and 5.7% had blebitis (infection of the bleb) by 5 years (). Very low pressure (hypotony, 6 mmHg) occurred in 42% of eyes. In another study, most MMC-treated blebs became avascular (lack normal blood vessels) within a year, and leak risk increased over time (). Patients must be warned: a thin bleb can leak fluid and even harbor germs. Overall, bleb-related infection after MMC-augmented filtering surgery is uncommon but real – roughly 1–2% per year () () (for example, one survey found 1.1% infection in MMC eyes at follow-up vs 1.3% without MMC ()). Key points for MMC: Standard practice is 0.2–0.4 mg/mL for 1–3 minutes. Higher doses give more pressure lowering but a higher chance of complication. The doctor always rinses thoroughly afterward. 5-Fluorouracil (5-FU) 5-Fluorouracil (5-FU) is another anti-scarring drug used in glaucoma surgery. It is a chemotherapy agent too, but less potent than MMC when used in the eye. In contrast to MMC’s sponge application, 5-FU is often given by injections under the conjunctiva either during or after surgery. A common regimen has been 5 mg (in 0.1 mL) injected once daily for 5–10 days postoperatively. Some older studies also used 5-FU on sponges at surgery. Evidence shows 5-FU significantly reduces scarring. In one randomized trial, trabeculectomy success rates using intraoperative 5-FU were essentially the same as with MMC (), demonstrating that 5-FU can be nearly as effective. A Cochrane review found that 5-FU injections significantly lowered the risk of surgical failure in high-risk eyes. For example, adding perioperative 5-FU to repeat glaucoma surgery cut failure risk by about one-third (relative risk ~0.67) (). In high-failure-risk eyes (like after a prior surgery), they calculated needing to treat only ~4 eyes to prevent one reoperation. 5-FU also produced substantial IOP drops: in the same review, “high-risk” patients getting 5-FU had mean IOP ~16 mmHg lower than controls at 1 year (). Because 5-FU tends to cause less severe thinning of the bleb wall than MMC, it is sometimes preferred for patients at very high risk of complications. Its side effects include corneal irritation (toxicity to the front of the eye), shallow anterior chamber, and bleb leak. The Cochrane summary noted that things like wound leaks and low pressures were more common with 5-FU, though the overall infection risk was low (). In practice today, 5-FU is often used in follow-up clinic if a newly formed bleb shows too much scarring: the surgeon may inject 5-FU in the office or perform needling (bleb revision) with 5-FU to improve flow. Key points for 5-FU: Common regimen is 5 mg daily for ~5 days post-op. It boosts success in tough cases (). It causes less avascular thinning than MMC, but blebs can still leak or stay flat. ROCK (Rho-Kinase) Inhibitors and Other Emerging Drugs ROCK inhibitors are a newer class of glaucoma medications originally developed to lower pressure by relaxing eye outflow channels. Preclinical studies suggest they also have anti-scarring effects. ROCK inhibitors (like ripasudil or netarsudil drops) can slow down fibroblast activity in the conjunctiva. Animal models of glaucoma surgery have shown that adding a ROCK inhibitor to the eye reduces postoperative scarring (). Commercially available ROCK inhibitor eye drops (e.g. netarsudil) are not yet standard in surgery, but researchers are testing whether such drops (or injections) could be given around the time of filtering surgery to improve bleb outcomes. Other agents under investigation include anti-VEGF drugs (like bevacizumab) and experimental molecules that block fibrotic growth factors. For example, a recent randomized clinical trial (2023) found that a single intravitreal bevacizumab injection at the time of trabeculectomy significantly improved results: only 6% of eyes in the bevacizumab group needed glaucoma medications at 1 year (versus 17% of controls), and only 2% needed additional surgery (versus 10% of controls) (). Bleb appearances were also better (larger blebs, less redness) in the bevacizumab group (). These findings suggest anti-VEGF can help modulate wound healing. Ongoing trials are comparing various drugs (topical or injected) in surgery, but as of 2026 these are still emerging and not yet routine in most practices. Sustained-Release and Targeted Delivery Because continuous exposure to anti-fibrotic agents might improve outcomes, researchers are developing sustained-release formulations. For example, a novel gel implant containing MMC was tested in rabbits with a tiny drainage stent. Eyes that got the MMC sustained-release implant maintained a ≥20% IOP drop for a median of 30 weeks, compared to only 6.5 weeks in eyes given a one-time MMC injection and 1 week in untreated eyes (). This shows how a slow-release system can keep the bleb functioning much longer. Other approaches include microparticles or coatings on drainage devices. In lab research, scientists coated a glaucoma tube shunt with microparticles of MMC. The microparticles slowly release the drug locally to the surrounding tissue, aiming to prevent fibrosis around the shunt. Such designs are experimental but promising (). Similarly, there is interest in MMC-loaded biodegradable gels or pads that could be placed during surgery (or injected) to deliver drug over days rather than minutes. As of 2026 these sustained-release products are mostly in animal or early human testing, but they represent a future strategy to make anti-fibrotics safer and more effective. Bleb Morphology and Infection Risks The goal of using anti-fibrotics is to create a well-formed, functioning bleb that continues to drain fluid. Typical bleb appearance with MMC is often a large, thin-walled, leaky bleb. This “cystic” bleb can be ideal for lowering pressure but also precarious. A large multi-lobed bleb covering much of the upper sclera with few surface blood vessels is often seen. With 5-FU, blebs may be a bit thicker and less avascular than with high-dose MMC, but can still be cystic. Few studies have looked at bleb shape by treatment, but one analysis showed that eyes treated with MMC often became avascular (neck), with leaks developing months later (). In that series, 71% of MMC-blebs were avascular by 1 year. Larger avascular blebs were roughly four times more likely to ooze or leak th Support the show

    Wound Healing Modulation 2026: Anti-fibrotics in Filtering Surgery
  3. 3 days ago

    Vision for 2030: What July 2026 Glaucoma Trends Mean for the Next Four Years

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/vision-for-2030-what-july-2026-glaucoma-trends-mean-for-the-next-four-years Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Glaucoma by 2030: Innovations and Trends Shaping Future Care Glaucoma – a group of eye diseases that damage the optic nerve and lead to vision loss – already affects tens of millions worldwide and will grow as populations age (). Today, most patients manage glaucoma with daily eye drops, occasional laser treatments, or surgery. But new research, new rules, and new care models are coming that could change how patients are screened, monitored, and treated by 2030. This article reviews cutting-edge trends (as of mid-2026) in glaucoma research & development (R&D), regulation, care delivery, and economics to forecast what glaucoma care might look like by 2030. In particular, we explore three emerging approaches – sustained-release (depot) therapies, artificial intelligence (AI)–enabled screening, and home monitoring – examining optimistic and cautious adoption scenarios for each, along with barriers and enablers. We also outline likely health policy milestones (e.g. screening guidelines, reimbursements) and workforce needs (glaucoma specialists and allied staff) to meet future demand. Finally, we suggest key metrics (like detection rates, treatment adoption, and disease control) that clinics and researchers should track each year to stay on course. Innovation Trends in Glaucoma R&D and Care New Treatment Options Recent years have seen major innovation in how we treat glaucoma. One big area is sustained-release drug delivery. Instead of daily eye drops (which many patients find hard to use exactly every day), doctors are developing implants and devices that slowly release pressure-lowering drugs over months. The first FDA-approved example is Durysta, a tiny biodegradable implant placed inside the eye that slowly releases bimatoprost (a prostaglandin analog) and can control eye pressure for about 4 months (). Another is iDose TR (Glaukos), an anchored titanium implant that releases travoprost; in trials it matched twice-daily eye drops while freeing 81% of patients from drops at 12 months (). Eye doctors expect even more of these devices soon. For example, a review notes that while Durysta is currently the only U.S.-approved sustained-release glaucoma therapy (), several other drug-eluting implants (trabecular meshwork inserts, punctal plugs, drug-coated lenses) are in clinical trials. One promising approach is the BIM-IOL (SpyGlass), an ordinary intraocular lens (like those used in cataract surgery) fitted with a bimatoprost drug pad. In a 2026 study, a single BIM-IOL inserted at cataract surgery allowed 97% of glaucoma patients to stop all other pressure drops for at least a year (). Other new medications are coming too. For example, novel eye drops with new targets (like nitric oxide donors and EP2 receptor agonists) are in late-stage trials or recently approved. These include Roclatan (lanostrasol); Omlonti (omidenepag isopropyl); and others in testing. A 2026 glaucoma pipeline review notes a rich “expanding array” of treatments, from new eye-drop drugs and combinations to implants () (). These advances reflect a shift toward earlier and interventional treatment – using lasers and devices instead of just waiting until vision worsens. Already, trials like the LiGHT study have shown that early laser trabeculoplasty can effectively lower pressure long-term, influencing practice patterns (). Despite all this innovation, some things remain experimental. Doctors remain hopeful but cautious about neuroprotective or regenerative therapies (aimed at healing nerve cells or restoring the drainage tissue) – none are standard yet () (). As one expert panel noted, stem cell or gene approaches are “areas of intense scientific interest” but still largely early-stage (). Guidelines are focusing more on proven tools. Non-medical strategies like patient education (about adherence and lifestyle) are also highlighted, since consistent medication use is crucial for good outcomes (). Artificial Intelligence and Digital Tools Artificial intelligence (AI) is another hot area. Researchers are developing AI software to analyze eye scans or photos and catch glaucoma earlier. For example, deep-learning algorithms have shown high sensitivity and specificity for detecting glaucoma from optic nerve images (). A 2025 review found AI methods that automatically segment the optic disc in photos and match experts’ accuracy () (). In other words, AI can look at a retina picture or OCT scan and flag glaucoma risk, sometimes even before obvious symptoms show. These algorithms can sift through data at lightning speed. One clinician points out that AI could combine imaging, patient records, and visual field tests to predict who is most at risk (). AI isn’t magic, though. Experts note many challenges: existing studies often use limited, non-diverse datasets; models must be “trained” on more early-stage disease cases; and AI tools must fit into clinic workflows. Current AI systems typically automate only parts of the exam (like reading an image) (). Challenges highlighted include data quality and generalizability (ensuring the AI works for different ethnic groups and camera types) (). There are also questions of liability (who’s responsible if AI misses a problem) and reimbursement (will insurers pay for the tests?) () (). So far, no AI device is FDA-approved specifically for glaucoma screening. But regulatory bodies like the U.S. FDA and international agencies are actively working on rules for “AI-based” medical devices. For example, FDA updates now tag devices that use modern AI technology (), and early principles for AI in health have been published by the FDA, Health Canada, and UK regulators. These steps pave the way for AI adoption by clarifying what oversight is needed. AI can already improve aspects of care. Systems used for diabetic retinopathy screening provide a model: clinics without eye doctors can take a retina photo, have AI analyze it, and identify patients needing referral. Early adopters report that such systems save patient time and increase exam capacity () (). We may see similar setups for glaucoma: AI software reading retinal photos in primary care or optometry settings to catch glaucoma “red flags” early. But it will take a few years of evidence and regulatory review to know exactly how to roll this out widely. Remote and Home Monitoring The COVID-19 pandemic accelerated interest in remote care. Glaucoma is a chronic disease, so doctors see patients perhaps 2–4 times a year to check eye pressure and vision. However, those snapshots may not capture the full picture of disease progression. New home-monitoring devices are emerging to fill the gaps. The best-known is home tonometry. These are portable instruments (like the iCare HOME rebound tonometer) that let patients check their own eye pressure at home, several times a day if needed. Clinical studies have found iCare Home readings correlate well with the gold-standard Goldmann tonometer done in a clinic (). Importantly, home checks can reveal pressure spikes that are missed when measurements are only taken during office visits. A recent review noted that peak out-of-office pressures are often higher than those measured in clinic, and devices like iCare HOME can catch these hidden peaks (). Regular home IOP monitoring could help doctors adjust treatment more precisely. Other home tests include virtual reality (VR) perimetry and smartphone vision tests. For example, head-mounted VR devices (like VisuALL) allow patients to do a visual field test at home – mapping their vision without needing a bulky in-clinic machine (). Trials of these tools have shown they can closely match standard visual field results. Similarly, smartphone/tablet apps (like the Melbourne Rapid Fields app) let patients do basic vision checks at home, with data sent to the clinic. A 2025 systematic review of telemonitoring found these home VF and home pressure tools are not only feasible but cost-effective: they reduce patient travel and wait-times and improve satisfaction (). In summary, technical feasibility is there – many studies report that home tests give results very similar to clinic tests (). Barriers remain, however. Many patients (older adults) may struggle to perform tests correctly without help. Devices like iCare HOME can be expensive (thousands of dollars), and insurance coverage for home monitoring is still limited. Some virtual field tests require a smartphone or computer and good understanding of the app. Finally, doctors must handle large amounts of patient-generated data. As one specialist notes, we now have the tools, but key questions are how to integrate them “in the right way” for routine care () (). Implementing these tools will require training staff, setting up data platforms, and getting payers to reimburse remote testing. Enablers include patients’ desire to avoid frequent clinic trips and the healthcare system’s push for telehealth. Many clinics have already started “teleglaucoma” programs where techs gather test data remotely for later review by doctors. The pending shortage of specialists (see below) may also drive wider use of optometrists and telemedicine teams, with home-monitoring devices help Support the show

    Vision for 2030: What July 2026 Glaucoma Trends Mean for the Next Four Years
  4. 5 days ago

    Personalizing a supplement plan after trabeculectomy

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/personalizing-a-supplement-plan-after-trabeculectomy Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Personalizing Your Post-Trabeculectomy Diet and Supplements After a trabeculectomy (glaucoma surgery), your eye is healing through several stages. In the first 2–4 weeks, new blood vessels and soft granulation tissue form under the conjunctiva () (). By about 3 weeks, collagen and scar tissue begin to develop. During this subacute phase (2–4 weeks), the bleb (fluid-filtering bubble) is still soft and vascular (). Good nutrition helps healing: a balanced diet rich in fruits, vegetables, vitamins (like C and A), protein, and fluids supports tissue repair () (). However, very high-dose or specialty supplements generally show only modest benefit () (). For example, a clinical trial found that taking 300 mg of vitamin E daily after trabeculectomy did not improve surgical success or complication rates compared to placebo (). Instead of relying on megadoses, follow your doctor’s orders for eye drops and medication. Use supplements only if needed and in safe doses. This means usually not exceeding the Recommended Daily Allowance for vitamins/minerals unless a deficiency is known. Discuss any new supplement with your doctor before starting. Consider Your Medical History and Medications Your overall health can affect healing and interactions with supplements: Blood thinners or anticoagulants (like warfarin, Xarelto, aspirin, Plavix): These make bleeding more likely. Many herbal supplements also have blood-thinning effects. For example, garlic, ginkgo biloba, ginger, ginseng, turmeric (curcumin), and high-dose vitamin E can all increase bleeding risk () (). One review found that garlic and hawthorn supplements were strongly linked to surgical bleeding, and that herbs like ginkgo, turmeric, and others raised bleeding risk in patients on blood thinners (). If you take any of these, tell your doctor. He or she may suggest stopping them or monitoring you closely. On the other hand, normal-dose fish oil (omega-3), ginseng, and saw palmetto did not show increased bleeding in studies (), though we still caution if you are on blood thinners. Practical point: If you are on warfarin, your doctor should check your INR after starting any new supplement. For example, substances like vitamin E or CoQ10 can raise INR and require a dose adjustment (). Vitamin K (in green vegetables) lowers warfarin effect, so keep your vitamin K intake steady. Blood pressure, heart meds, and kidney meds: Some supplements affect blood pressure or potassium levels. For example, potassium-rich supplements or teas (like high-dose potassium or warm medicinal teas) can add to potassium if you’re on ACE-inhibitors or potassium-sparing diuretics. Herbals like licorice can also raise blood pressure. Always check with your doctor: if you have high blood pressure or heart disease, do not take supplements that significantly raise or lower blood pressure without approval. Diabetes: If you have diabetes, avoid supplements that spike blood sugar. Some herbal formulas (like certain Chinese or Ayurvedic mixes) can raise or lower blood sugar, so discuss any new herbals with your endocrinologist. Generally, stick to multivitamins and avoid sweet syrups or products with lots of sugar. Other conditions: Chronic inflammatory conditions or steroid use can slow healing or suppress immune response. In these cases, your doctor may want to avoid immune-boosting herbs (like echinacea) or anti-inflammatory ones (like high-dose turmeric) that could theoretically interfere with your medications. If you have liver or kidney problems, high doses of fat-soluble vitamins (A, D, E, K) or minerals might need lab monitoring. Bottom line: Write down all your health conditions and medications. Review them with your doctor to flag any supplement interactions. For instance, if you use aspirin or warfarin, your doctor will advise stopping “blood-thinning” herbs well before or after surgery (). Surgical Details Matter Details of your surgery guide what to watch for: Anti-scarring agents (MMC/5-FU): Many trabeculectomies use anti-fibrotic drugs (mitomycin-C or 5-fluorouracil) during surgery to prevent aggressive scarring (). If your surgeon used these, the wound is intentionally kept from scarring too fast. In that case, you may tolerate normal healing better and have less natural scarring. You usually do not need extra anti-scarring supplements, since the medication already reduces fibrosis. No anti-scarring agents: If no mitomycin-C or 5-FU was used, your eye relies on its own healing. Certain types of glaucoma, like neovascular or uveitic glaucoma, or repeat surgery cases, are known to scar excessively and often drive surgeons to use anti-fibrotics (). In these high-risk eyes, supplements that might inhibit scarring (like curcumin) could be considered, but evidence is weak. It’s safer to ensure good steroid use (as prescribed eye drops) and a healthy diet rich in anti-oxidants (fruits, vegetables) () () rather than special pills. Needling or leaks: If in follow-up the doctor performed a needling procedure (to break scar tissue) or there’s a bleb leak, it means your eye is having trouble. In such cases, avoid any supplement that could worsen bleeding or fluid leaks. Focus on healing (adequate rest, avoiding strain). For example, if your bleb is leaking, keep eyes lubricated and avoid thickening supplements that dry out fluids; also notify your surgeon before adding anything new. Assess Healing Status At two weeks, your surgeon will examine the bleb. Here’s what to consider for supplements: Bleb appearance & fluids: If the bleb is very vascular (red) or has a tiny leak, skip blood-thinning supplements (fish oil, ginkgo, garlic, etc.) until it’s stable. The aim is to avoid new minor hemorrhages around the surgical site. Intraocular pressure (IOP): Keep track at each visit. A slight upward trend in IOP during the first month could signal scarring (). Avoid supplements that might raise IOP (some people worry about caffeine or certain steroids; check with doctor). Conjunctival and wound health: No serious infection or inflammation should be present. If your eye shows signs of infection (redness, discharge) or excessive inflammation, do not take new supplements that you haven’t used before the surgery. Contact your doctor right away. Weighing Bleeding vs. Fibrosis Risks Weigh your risk of bleeding complications against risk of scar formation: High bleeding risk: This includes patients on blood thinners, with bleeding disorders, or those who had a bloody operative course. Also older patients can have more fragile vessels. In high bleeding-risk cases, be cautious with any supplement that thins blood. For example, a Baylor University review cautions that many supplements can “alter bleeding and coagulation during surgery” (). Garlic and hawthorn were “strongly associated” with surgical bleeding, and others (ginkgo, turmeric, fenugreek, etc.) posed risks in patients on anticoagulants (). If you fall into this category, skip herbals like ginkgo/ginseng/ginger and stop any high-dose multivitamins or fish oil until your doctor gives clearance. Your doctor may even suggest stopping non-essential supplements 2 weeks before and after surgery (). High fibrosis (scarring) risk: Younger patients, Black or African ancestry, and patients with inflammatory glaucoma (like uveitic) or prior failed trabs tend to scar more () (). If you’re in this group, your doctor likely already used an antifibrotic medicine. Still, you can support healthy healing: ensure enough protein (but not extreme “bone broth”), stay hydrated, and possibly use mild anti-inflammatories (see below). There’s no proven supplement that mimics mitomycin, but maintaining a healthy diet of fruits and vegetables (vitamins A, C) and omega-3 fatty acids can modulate inflammation. Safe Supplements to Consider When healing is on track and risk factors are managed, these may be safe: Basic vitamins/minerals: A standard multivitamin (100% of daily values) is fine if your diet is poor or you have a known deficiency. Vitamins C and A are important for collagen and tissue repair; vitamin C deficiency especially delays healing (). However, don’t take mega-doses. For example, excess vitamin A can be toxic – stick to normal amounts. Zinc: An essential mineral for wound repair. Zinc serves in cell growth and immune function. Studies show zinc deficiency is linked to delayed healing (). If you’re deficient (or diet poor), a modest zinc supplement (e.g. 8–11 mg daily) can be helpful. But high-dose zinc can cause nausea or anemia, so don’t overdo it. Omega-3 (fish oil): These fatty acids help resolve inflammation. Some research in wound care notes omega-3s have “profound effects on wound healing” (). Small doses (e.g. 1000 mg fish oil daily) can be safe and may calm inflammation around the bleb. Large doses may thin blood slightly; if you’re on blood thinners, check with your doctor. Large trials have found no significant bleeding risk from normal fish oil use () (), but caution is wise with any anticoagulant use. Arginine: An amino acid involved in collagen production and immune function. Some wound-healing protocols include arginine to support tissue growth. There’s no specific study in trabs, but a review notes arginine (with omega-3s) can improve wound outcomes (). You might get Support the show

    Personalizing a supplement plan after trabeculectomy
  5. 17 Jul

    Vitamin D status and trabeculectomy outcomes

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/vitamin-d-status-and-trabeculectomy-outcomes Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Vitamin D Status and Trabeculectomy Outcomes Vitamin D is a crucial nutrient (actually a hormone) known for maintaining bone health, but it also modulates the immune system and inflammation in many tissues, including the eye【6】【25】. Glaucoma – a progressive optic nerve disease – is driven partly by high eye pressure and damaging inflammation. Some studies have found that people with glaucoma tend to have lower blood vitamin D levels than healthy controls【9】. Animal and cell studies suggest the vitamin D hormone (calcitriol) can protect retinal ganglion cells (the nerves damaged in glaucoma) and reduce inflammatory signals in the eye【6】. In fact, in trabecular meshwork (drainage) cells under stress, vitamin D3 blocked many abnormal changes (excessive matrix, collagen, inflammatory cytokines) that contribute to glaucoma pathology【6】. These findings imply vitamin D could help guard the optic nerve and enhance fluid outflow. However, clinical evidence on glaucoma progression is mixed. For example, one recent study found that glaucomatous progression (changes in visual fields or nerve structure over time) was not significantly different in patients with vitamin D deficiency versus those with normal levels【3】. Likewise, an ocular disease review concluded there’s no clear link between serum vitamin D levels and glaucoma severity or rate of worsening【6】. In summary, observational data are inconsistent: while many case-control studies report lower vitamin D in glaucoma patients【9】, cohort data do not clearly show that deficiency causes the disease to progress faster【6】【3】. Vitamin D, Immune Modulation, and Wound Healing A trabeculectomy creates a flap that drains fluid under the conjunctiva. Proper healing is crucial: too much scarring (fibrosis) can close the new drainage pathway, while too little healing can lead to leaks or infection. Vitamin D’s immunomodulatory role may influence these processes. It is known to suppress excessive inflammation and promote tissue repair in general【32】【25】. For example, ocular surface studies note that vitamin D dampens chronic inflammation but can enhance early healing inflammation and innate defenses【32】. In a mouse model of corneal abrasion, topical vitamin D actually increased neutrophils in the wound and slightly slowed initial closure (~17% delay at 18h), but it also upregulated antimicrobial peptides【32】. In practical terms, this suggests vitamin D is a double-edged sword: it might prolong the acute inflammatory phase (fine if controlled) but also strengthen early immune defense. Importantly, vitamin D has anti-scarring effects in the context of eye surgery. In lab culture of human Tenon’s fibroblasts (cells that cause scarring after trabeculectomy), vitamin D3 significantly inhibited cell proliferation and migration without harming cell viability【17】. These results indicate that higher vitamin D levels could help prevent the subconjunctival fibrosis that blocks filtration blebs. The authors suggested vitamin D3 might serve as a low-toxicity adjunct to standard anti-fibrotic agents after glaucoma surgery【17】. Vitamin D also supports the health of the ocular surface. Adequate vitamin D stabilizes tear film and nerves on the cornea【25】. Vitamin D deficiency has been linked to worse dry eye symptoms: studies show patients with chronic dry eye often have lower vitamin D than normal, and have worse tear production and symptom scores【24】. Supplementing vitamin D improved dry eye in both clinical and experimental models【25】. For example, in one small study of cataract surgery patients, those given vitamin D supplements maintained better tear volume and comfort than controls【34】. By analogy, after trabeculectomy (when topical glaucoma meds and surgery can cause dryness), ensuring sufficient vitamin D may help the ocular surface recover more quickly【24】【25】. Postoperative Repletion: Timing, Doses, and Safety When to start repletion? There is no formal guideline for glaucoma surgery specifically, but general practice is to correct clear deficiencies. Waiting about two weeks after trabeculectomy is reasonable: the acute inflammation and epithelial healing have usually settled by then, and starting vitamin D does not appear to disrupt normal wound repair【32】. In fact, delaying beyond initial healing may forgo the protective anti-inflammatory effects. The approach might be: measure vitamin D (25-OH vitamin D) soon after surgery, and if it is low, begin repletion a week or two later during routine follow-up. How much to give? Common repletion strategies follow endocrinology guidance. If blood 25-OH vitamin D is below ~20 ng/mL (50 nmol/L), a “loading dose” is often used – for example, 50,000 IU of vitamin D3 once weekly for 6–8 weeks – to rapidly raise levels【59】. Alternatively, some regimens use ~5,000–8,000 IU daily for a similar period. After this loading phase, a maintenance dose of ~1,000–2,000 IU daily is typically continued【59】. These amounts are within safe limits for most adults. Another option is a modest daily dose (e.g. 2,000 IU) started immediately; this will gradually raise levels without a sharp initial spike. The best strategy depends on how deficient the patient is and any risk factors they have (absorption issues, obesity, etc.). Safety – hypercalcemia risk: Vitamin D by itself very rarely causes problems at usual doses. The Institute of Medicine’s upper limit is about 4,000 IU/day for adults【99】. Taking vitamin D in recommended ranges is generally safe. Problems can occur if extremely high doses are taken or if other factors raise calcium. For example, older patients on thiazide diuretics (a blood pressure medication) are at higher risk: thiazides reduce calcium excretion, and if such a patient also takes high-dose vitamin D (especially with extra calcium supplements), their blood calcium can climb too high【45】. Indeed, case reports describe elderly patients on thiazides who developed hypercalcemia when taking vitamin D plus calcium【45】. To stay safe, patients should avoid exceeding ~4,000 IU/day for long periods unless under physician supervision. It’s wise to avoid unnecessary calcium supplements at the same time. The safe approach is to pick a reasonable dose (often 1,000–2,000 IU daily) and check levels after several months rather than using extremely large one-time doses in someone on a thiazide. Where needed, monitoring blood calcium can catch any issue early【45】. Interactions: Other glaucoma medications generally do not interact with vitamin D. However, if the patient takes any calcium-based antacids or high-dose multivitamins, that adds to the calcium‐vitamin D load. In summary: caution is mainly for thiazide diuretics or kidney insufficiency – both increase hypercalcemia risk with vitamin D【45】. Otherwise, vitamin D repletion is quite safe when dosed appropriately. The risk of actual vitamin D toxicity (very high levels causing hypercalcemia, kidney problems, etc.) requires far more vitamin D than typical supplements provide【48】. In ordinary cases, levels up to ~150 ng/mL (375 nmol/L) have been needed before true toxicity appears【48】. Thus modest repletion aimed at normalizing levels (20–40 ng/mL) poses minimal danger. Take-Home and Testing Recommendations Put simply, vitamin D deficiency is treatable and may help after glaucoma surgery. To be practical: Test when indicated: Patients with risk factors (older age, limited sun exposure, malabsorption, osteoporosis history) should have their 25-OH vitamin D measured. The Endocrine Society defines deficiency as 30 ng/mL) and keep it there. Monitor: Re-check vitamin D after a few months to confirm the level is up. Also monitor calcium if there are risk factors (kidney disease, thiazide use, hyperparathyroidism). Individualize: Elderly or those on interacting meds (thiazides, digoxin, etc.) may need smaller doses and closer follow-up. Weight and body fat can affect dosing (obese patients sometimes need higher doses). Work with your doctor or nutritionist to tailor the dose. Conclusion While no definitive clinical trials yet show that fixing vitamin D levels will speed trabeculectomy healing or prevent glaucoma worsening, the potential benefits and low risks support at least considering it. Vitamin D deficiency is common in older adults, especially those with less sun exposure. Given its role in immune regulation, tissue repair, and ocular surface health【25】【32】【17】, optimizing vitamin D status makes sense as part of comprehensive glaucoma care. In practice, we suggest: test or estimate vitamin D status, and if low, start a sensible repletion plan about two weeks after surgery. Keep doses in a Support the show

  6. 16 Jul

    Alpha-lipoic acid: Oxidative stress, neuropathy, and glycemic control

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/alpha-lipoic-acid-oxidative-stress-neuropathy-and-glycemic-control Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Alpha-lipoic acid (ALA) is a powerful antioxidant vitamin-like compound found naturally in foods like spinach and broccoli, and sold as a dietary supplement. It can neutralize damaging free radicals and help regenerate other antioxidants (like vitamins C and E), acting as a “cleanup crew” against oxidative stress () (). These properties have made ALA of great interest for protecting nerves in chronic diseases such as glaucoma and diabetes. Glaucoma involves slow loss of the optic nerve cells (retinal ganglion cells) often aided by oxidative damage, while diabetes causes high blood sugar and nerve damage. In this article we review the evidence on ALA’s effects in the eye and in blood sugar control, and discuss safety considerations. ALA for Glaucoma: Reducing Oxidative Stress and Protecting Nerves In glaucoma, damage to the optic nerve is linked not only to high eye pressure but also to reduced blood flow and oxidative stress in the retina. In fact, experts note “vascular factors may have important roles in the pathophysiology of glaucoma,” underlining the need to measure and improve ocular blood flow (). ALA, as an antioxidant, can help counter these processes. Laboratory studies show promising neuroprotective effects of ALA in glaucoma models. In one well-known study, mice prone to glaucoma were fed ALA in their diet. The treated mice showed higher expression of antioxidant genes and proteins in the retina, with lower levels of oxidative damage markers (damaged lipids, proteins, and DNA) compared to controls (). These mice also had better survival of retinal ganglion cells: after months of treatment the ALA-fed mice had healthier optic nerves and about 13% more optic nerve axons than untreated mice (). In other words, ALA slowed the loss of nerve fibers in glaucoma. The researchers concluded that ALA “reduces oxidative stress and improves RGC [retinal ganglion cell] survival in glaucoma” (). Clinical data in human glaucoma patients is still sparse, but some results are encouraging. For example, a small six-month study gave glaucoma patients a supplement containing R-alpha-lipoic acid (the active form of ALA) plus other antioxidants (vitamins C, E, lutein, omega-3, etc.). After 6 months the patients had significantly higher blood antioxidant capacity and much lower levels of malondialdehyde (a blood marker of oxidative damage) (). They also reported improved tear production (important for ocular surface health) and fewer dry-eye symptoms. Importantly, the supplement was well tolerated with no reported side effects or intolerances (). The authors noted that the antioxidant formula “counteracted oxidative stress […] and stabilized the functional parameters of the ocular surface and the glaucoma, without adverse effects” (). While this study included other nutrients beside ALA, it supports the idea that using ALA in a glaucoma-safe formula can boost antioxidant defenses in the eye. Animal and human studies together suggest ALA can help protect ocular nerves by reducing oxidative stress () (). Future clinical trials should look for objective eye measures of benefit. For example, optical coherence tomography (OCT) can measure the thickness of the retinal nerve fiber layer (RNFL) – a thinner RNFL indicates nerve loss in glaucoma. Inman et al. showed ALA helped preserve optic nerve fibers in mice (), so in patients one could test whether ALA slows RNFL thinning on OCT. Likewise, improved optic nerve blood flow could be an endpoint: newer techniques like OCT angiography measure tiny retinal blood vessels. Indeed, glaucoma patients have significantly reduced peripapillary blood flow indexes on OCT-A (), so an increase in these blood-flow measurements would be a useful sign of improved ocular perfusion. In short, changes in ocular perfusion (by imaging or Doppler) and in RNFL thickness would be key endpoints to watch in eye studies of ALA. ALA in Diabetes: Blood Sugar Control and Neuropathy Aside from eye disease, ALA is widely studied in diabetes, especially for diabetic neuropathy (nerve pain). It also affects blood sugar levels. ALA improves insulin sensitivity and helps cells take up glucose, so it can modestly help lower blood sugar. Several human trials and reviews have tested ALA in type 2 diabetes: A 2022 meta-analysis of 16 randomized trials (total ~1000 patients) found that each additional 500 mg per day of ALA produced statistically significant drops in hemoglobin A1c (average blood sugar) and fasting glucose (). In other words, increasing the daily ALA dose by 500 mg lowered A1c by about 0.3 percentage points and also reduced weight, inflammation (CRP), and triglycerides (). These findings are notable, but the actual changes in blood sugar were relatively small. Another comprehensive review noted that, in routine clinical trials, ALA’s effect on A1c tends to be limited or inconsistent (). Many studies (often with low doses or short duration) found no significant changes in A1c () (). For example, some trials saw mild A1c improvement only at high doses, while others saw no change. Overall, these authors concluded that ALA’s benefits for long-term sugar control in diabetics are promising but mixed () (). The bottom line for patients: ALA can support blood sugar control, but it is not a substitute for diabetes medications. If you have type 2 diabetes, adding ALA (typically 600–1200 mg daily) may slightly improve blood sugar and help with weight/markers (), but results vary. Its more established use is for diabetic neuropathy. Multiple trials have shown that ALA (usually 600–1200 mg IV or oral) significantly improves nerve conduction and reduces neuropathy symptoms (). Many diabetic patients take ALA for nerve pain relief in practice. Safety and Drug Interactions After eye surgery (trabeculectomy): There is little direct data on ALA for patients after glaucoma surgery. However, an animal study is reassuring. In rabbits undergoing trabeculectomy (a common glaucoma surgery), adding ALA eye drops was well tolerated. Over 4 weeks, no rabbits developed infection, cataract, or inflammation from the ALA drops (). The treated group even had better surgical bleb survival than untreated controls (fewer blebs failed). In other words, topical ALA appeared safe and possibly beneficial for wound healing after trabeculectomy in this model (). While human studies are needed, this suggests that using ALA (especially topically) after surgery is unlikely to hurt and may reduce scar tissue. Of course, any supplement after surgery should be discussed with the surgeon. Hypoglycemia risk: Because ALA enhances insulin action, diabetic patients (or those on diabetes drugs) should watch for low blood sugar. Health agencies have noted rare cases of ALA triggering an insulin autoimmune syndrome (IAS) in susceptible people (). In IAS, the body makes antibodies to insulin, causing unexpected low blood sugars. These cases were often genetic and mostly reported in East Asian patients. Importantly, all of the reported hypoglycemia cases resolved after stopping ALA (). In practical terms, if you take ALA with insulin or sulfonylureas, monitor your blood sugar especially when starting or increasing the dose. Symptoms of hypoglycemia (sweating, dizziness, confusion) should prompt stopping ALA and contacting a doctor (). This side effect is very rare, but worth knowing about if you have diabetes. Thyroid medication: Some lab studies suggest ALA might interfere with thyroid hormone. Levothyroxine (T4) is converted in the body to its active form T3, and animal data indicate ALA can slow that conversion (). In practice, this is a theoretical concern: people on thyroid medication should tell their doctor if they start ALA. It may be prudent to take the thyroid pill and ALA at different times of day and to have periodic thyroid blood tests, although strong evidence of a problem is lacking (). Chemotherapy and other drugs: ALA’s antioxidant action raises questions for patients on chemotherapy. Some oncologists worry antioxidants might reduce chemotherapy effectiveness, since certain chemo drugs kill cancer cells via oxidative damage. Research is mixed. HelloPharmacist notes that any ALA–chemotherapy interaction is theoretical: “alpha-lipoic acid’s antioxidant activity might in theory change how well these [cancer] treatments work, though experts disagree” (). In fact, some clinical trials have even given ALA to cancer patients to prevent chemo-induced neuropathy (). The safest approach: if you are on chemotherapy, discuss ALA use with your oncologist. They may allow it for side-effect relief (at trusted doses) or advise caution. Beyond chemo, ALA can have mild blood-thinning effects in lab studies, so it might boost bleeding risk if taken with anticoagulant or antiplatelet drugs (). Again, solid evidence in humans is lacking, but if you’re on a blood thinner (like warfarin or aspirin), mention ALA to your doctor to decide if any extra monitoring is needed. Forms, Dosing, and Bioavailability ALA supplements come in different forms. The natural form of ALA in the body is the R-enantiomer (R-ALA); a mirror-image S-ALA form exists only in synthetic mixtures. Most Support the show

  7. 15 Jul

    Bromelain and proteolytic enzymes: Postoperative edema vs bleeding concerns

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/bromelain-and-proteolytic-enzymes-postoperative-edema-vs-bleeding-concerns Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Bromelain, serrapeptase, and similar proteolytic (protein-digesting) enzymes are natural supplements sometimes promoted to reduce surgical swelling and pain. People often take them after operations (for example, dental extractions or soft-tissue surgery) in hopes of speeding healing. These enzymes indeed have anti-inflammatory effects and can ease pain. However, they also can thin the blood or interfere with clotting. That raises a particular concern after glaucoma filtration surgery (trabeculectomy), where a delicate “filtering bleb” must heal without bleeding. In this article, we review the evidence on their benefits and risks for postoperative recovery, with a special focus on bleeding (hyphema) and bleb complications after trabeculectomy. We will cover when (and if) it might be safer to start these supplements after surgery, which patients should avoid them, and how future studies could safely measure outcomes. How Bromelain and Serrapeptase Work Bromelain is a mixture of enzymes from pineapple stems (Ananas comosus). Serrapeptase (serratiopeptidase) is an enzyme from a bacterium found in silkworm intestines. Both are proteolytic enzymes that break down proteins. In the body, this gives them several effects: they can reduce inflammation and edema (swelling), dissolve certain blood clots, and potentially prevent excessive scarring. They are often taken orally as capsules (usually in an enteric coating so they survive the stomach). Studies show these enzymes are absorbed in the gut and remain active in the bloodstream for hours () (). They help control inflammation by breaking down inflammatory mediators like bradykinin and serotonin (in the case of serrapeptase) () (). Both enzymes have been used in some settings to aid wound healing (for example, topical bromelain for burn debridement, and oral use in osteoarthritis and respiratory conditions). ... Continue reading at https://visualfieldtest.com/en/bromelain-and-proteolytic-enzymes-postoperative-edema-vs-bleeding-concerns Support the show

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.